Role of High-affinity HLA-DP Specific CLIP-derived Peptides in Beryllium Binding to the HLA-DPGlu69 Berylliosis-associated Molecules and Presentation to Beryllium-sensitized T Cells

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2009 Feb 5

PMID 19191908

Citations 6

Authors

Massimo Amicosante

Floriana Berretta

Raed Dweik

Cesare Saltini

Affiliations

Soon will be listed here.

Abstract

Berylliosis is driven by the accumulation in the lung of beryllium-specific T helper type 1 (Th1) cells recognizing beryllium as antigen when presented principally by human leucocyte antigen DP molecules carrying a glutamate at position beta69 (HLA-DPGlu69). This study was designed to clarify the precise role of peptides in beryllium binding to the HLA-DP groove's pocket 4 and to identify peptides with higher affinity for pocket 4 that might prevent beryllium presentation and T-cell stimulation. Beryllium/HLA-DP interactions were analysed by the ability of beryllium to compete with CLIP and CLIP-derived peptides to HLA-DPGlu69 soluble molecule. The CLIP-derived low-affinity peptide CLIP-AA, could not outcompete beryllium; while the CLIP-derived high-affinity peptides CLIP-YY, CLIP-QY and CLIP-RF were only marginally influenced by the presence of beryllium in the competition assay. The effect of these CLIP-derived high-affinity peptides on beryllium presentation was determined by measuring interferon-gamma (IFN-gamma) release upon beryllium stimulation of peripheral blood mononuclear cells obtained from beryllium-hypersensitive subjects. CLIP-YY did inhibit beryllium presentation and T-cell activation, while CLIP-QY and CLIP-RF markedly enhanced the IFN-gamma response to beryllium. Anti-HLA-DP monoclonal antibody blocked the beryllium-induced IFN-gamma release in the presence of CLIP-QY (88%) and CLIP-RF (76%). A similar effect was observed for CLIP-YY capability to block IFN-gamma release by beryllium stimulation in the presence of CLIP-QY (79%) and CLIP-RF (76%). Overall, these data support the proposal that HLA-DP high-affinity peptides might be used as a model for specific berylliosis therapy.

Citing Articles

Pulmonary granulomatosis of genetic origin.

Bode S, Rohr J, Muller Quernheim J, Seidl M, Speckmann C, Heinzmann A Eur Respir Rev. 2021; 30(160).

PMID: 33927005 PMC: 9488645. DOI: 10.1183/16000617.0152-2020.

Beryllium-Induced Hypersensitivity: Genetic Susceptibility and Neoantigen Generation.

Fontenot A, Falta M, Kappler J, Dai S, McKee A J Immunol. 2015; 196(1):22-7.

PMID: 26685315 PMC: 4685955. DOI: 10.4049/jimmunol.1502011.

Peptide binding to HLA-DP proteins at pH 5.0 and pH 7.0: a quantitative molecular docking study.

Patronov A, Dimitrov I, Flower D, Doytchinova I BMC Struct Biol. 2012; 12:20.

PMID: 22862845 PMC: 3508589. DOI: 10.1186/1472-6807-12-20.

Peptide binding prediction for the human class II MHC allele HLA-DP2: a molecular docking approach.

Patronov A, Dimitrov I, Flower D, Doytchinova I BMC Struct Biol. 2011; 11:32.

PMID: 21752305 PMC: 3146810. DOI: 10.1186/1472-6807-11-32.

Chronic beryllium disease: an updated model interaction between innate and acquired immunity.

Sawyer R, Maier L Biometals. 2010; 24(1):1-17.

PMID: 20981472 PMC: 3057103. DOI: 10.1007/s10534-010-9376-3.

References

Rossman M, Stubbs J, Lee C, Argyris E, Magira E, Monos D . Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med. 2002; 165(6):788-94. DOI: 10.1164/ajrccm.165.6.2104002. View

Fontenot A, Canavera S, Gharavi L, Newman L, Kotzin B . Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J Clin Invest. 2002; 110(10):1473-82. PMC: 151812. DOI: 10.1172/JCI15846. View

Lombardi G, Germain C, Uren J, Fiorillo M, du Bois R, Jones-Williams W . HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J Immunol. 2001; 166(5):3549-55. DOI: 10.4049/jimmunol.166.5.3549. View

McCanlies E, Ensey J, Schuler C, Kreiss K, Weston A . The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. Am J Ind Med. 2004; 46(2):95-103. DOI: 10.1002/ajim.20045. View

Castelli F, Buhot C, Sanson A, Zarour H, Pouvelle-Moratille S, Nonn C . HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol. 2002; 169(12):6928-34. DOI: 10.4049/jimmunol.169.12.6928. View

Diaz G, Amicosante M, Jaraquemada D, Butler R, Guillen M, Sanchez M . Functional analysis of HLA-DP polymorphism: a crucial role for DPbeta residues 9, 11, 35, 55, 56, 69 and 84-87 in T cell allorecognition and peptide binding. Int Immunol. 2003; 15(5):565-76. DOI: 10.1093/intimm/dxg057. View

Wang Z, Farris G, Newman L, Shou Y, Maier L, SMITH H . Beryllium sensitivity is linked to HLA-DP genotype. Toxicology. 2001; 165(1):27-38. DOI: 10.1016/s0300-483x(01)00410-3. View

Berretta F, Butler R, Diaz G, Sanarico N, Arroyo J, Fraziano M . Detailed analysis of the effects of Glu/Lys beta69 human leukocyte antigen-DP polymorphism on peptide-binding specificity. Tissue Antigens. 2003; 62(6):459-71. DOI: 10.1046/j.1399-0039.2003.00131.x. View

Maier L, McGrath D, Sato H, Lympany P, Welsh K, du Bois R . Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol. 2003; 171(12):6910-8. DOI: 10.4049/jimmunol.171.12.6910. View

10.

Lu L, Vollmer J, Moulon C, Weltzien H, Marrack P, Kappler J . Components of the ligand for a Ni++ reactive human T cell clone. J Exp Med. 2003; 197(5):567-74. PMC: 2193829. DOI: 10.1084/jem.20021762. View

11.

Bill J, Mack D, Falta M, Maier L, Sullivan A, Joslin F . Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II beta-chain. J Immunol. 2005; 175(10):7029-37. DOI: 10.4049/jimmunol.175.10.7029. View

12.

Amicosante M, Deubner D, Saltini C . Role of the berylliosis-associated HLA-DPGlu69 supratypic variant in determining the response to beryllium in a blood T-cells beryllium-stimulated proliferation test. Sarcoidosis Vasc Diffuse Lung Dis. 2005; 22(3):175-9. View

13.

Ali F, Larche M . Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Rev Vaccines. 2005; 4(6):881-9. DOI: 10.1586/14760584.4.6.881. View

14.

Richeldi L, Sorrentino R, Saltini C . HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science. 1993; 262(5131):242-4. DOI: 10.1126/science.8105536. View

15.

Amicosante M, Fontenot A . T cell recognition in chronic beryllium disease. Clin Immunol. 2006; 121(2):134-43. DOI: 10.1016/j.clim.2006.03.012. View

16.

Saltini C, Richeldi L, Losi M, Amicosante M, Voorter C, Van den Berg-Loonen E . Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J. 2001; 18(4):677-84. DOI: 10.1183/09031936.01.00106201. View

17.

Wang Z, White P, Petrovic M, Tatum O, Newman L, Maier L . Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol. 1999; 163(3):1647-53. View

18.

Chou Y, Edwards D, Weinberg A, Vandenbark A, Kotzin B, Fontenot A . Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis. J Immunol. 2005; 174(7):4316-24. DOI: 10.4049/jimmunol.174.7.4316. View

19.

Diaz G, Canas B, Vazquez J, Nombela C, Arroyo J . Characterization of natural peptide ligands from HLA-DP2: new insights into HLA-DP peptide-binding motifs. Immunogenetics. 2004; 56(10):754-9. DOI: 10.1007/s00251-004-0735-5. View

20.

Farina C, Weber M, Meinl E, Wekerle H, Hohlfeld R . Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 2005; 4(9):567-75. DOI: 10.1016/S1474-4422(05)70167-8. View